Data supporting the investigation of interaction of biologically relevant proteins with ZnO nanomaterials: A confounding factor for in vitro toxicity endpoints
Related Experiment Video
Updated: Jan 21, 2026

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Emilie Da Silva1,2, Yahia Kembouche1, Ulla Tegner1
1The National Research Center for the Working Environment, Lersø Parkallé 105, Copenhagen, Denmark.
Abstract:
Test materials, like manufactured nanomaterials (MN), may interact with serum proteins, interleukins (IL) and lactate dehydrogenase (LDH) and cause measurement artefacts as a result of e.g., physical adsorption and electrostatic forces, and/or interaction with dissolved species or conditional chemical changes during testing. In this article, data are given on the zeta-potentials of two manufactured ZnO nanomaterials (NM-110 and NM-111) dispersed in 0.05% w/v Bovine Serum Albumin (BSA) water batch dispersions and in Ham's F12 nutrient mixture added Fetal Bovine Serum (FBS), penicillin, and streptomycin and particle free mediums (cHam's F12). Data on the Zeta-potential and the iso-electrical point of lactate hydrogenase in pure Ham's F12 nutrient mixture is also provided. The percentage of added IL-6, IL-8 and LDH remaining after 24-h incubation in cHam's F12 are given as function of MN concentrations. Finally data from thermodynamic chemical reaction modeling of changes in pH and Zn-speciation during dissolution of ZnO or dissolved ZnCl2 additions to Ham's F12 using Geochemist Workbench® are given. For further information, data interpretation and discussion please refer to the research article "Interaction of biologically relevant proteins with ZnO nanomaterials: a confounding factor for in vitro toxicity endpoints" (E. Da Silva et al. 2019).
Related Concept Videos
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Confounding in Epidemiological Studies
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

